CD5 and myeloid sarcoma: Three recent publications showed that in fingolimod-treated MS patients: 1) naïve B cells as well as PD1-expressing B cells are increased; 2) circulating B cells produce higher amounts of IL-10 and lower quantities of TNFα; and 3) IL-10-secreting CD38+/CD27-/CD24+/CD5+ Breg cells are augmented50, 51, 52.